Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
05
2019
accepted:
25
11
2019
entrez:
13
12
2019
pubmed:
13
12
2019
medline:
27
3
2020
Statut:
epublish
Résumé
Access to adequate treatment for opioid use disorder (OUD) has been a high priority among American policymakers. Elucidation of the sociodemographic and institutional differences associated with the use, or lack thereof, of opioid agonist therapy (OAT) provides greater clarity on who receives OAT. Timely access to care is a further consideration and bears scrutiny as well. We draw upon data from the Treatment Episode Data Set-Admissions (TEDS-A) to analyse the relationship between sociodemographic and institutional characteristics and the receipt of opioid agonist treatments and time waiting to enter treatment. Estimates from logistic regression models highlight certain groups which show lower odds of receipt of OAT, including those in precarious housing arrangements, those unemployed or not otherwise in the labor force, and those referred by drug abuse care providers, educational institutions, employers, and the criminal justice system. Groups which showed higher odds of waiting over a week to enter treatment included those who were separated, divorced, or widowed, those working part-time, and those referred by drug abuse care providers, employers, and the criminal justice system. Given the efficacy of OAT and the adverse outcomes associated with long waiting times, coordinated effort is needed to understand why these differences persist and how they may be addressed through appropriate policy responses.
Sections du résumé
BACKGROUND
Access to adequate treatment for opioid use disorder (OUD) has been a high priority among American policymakers. Elucidation of the sociodemographic and institutional differences associated with the use, or lack thereof, of opioid agonist therapy (OAT) provides greater clarity on who receives OAT. Timely access to care is a further consideration and bears scrutiny as well.
METHODS
We draw upon data from the Treatment Episode Data Set-Admissions (TEDS-A) to analyse the relationship between sociodemographic and institutional characteristics and the receipt of opioid agonist treatments and time waiting to enter treatment.
RESULTS
Estimates from logistic regression models highlight certain groups which show lower odds of receipt of OAT, including those in precarious housing arrangements, those unemployed or not otherwise in the labor force, and those referred by drug abuse care providers, educational institutions, employers, and the criminal justice system. Groups which showed higher odds of waiting over a week to enter treatment included those who were separated, divorced, or widowed, those working part-time, and those referred by drug abuse care providers, employers, and the criminal justice system.
CONCLUSION
Given the efficacy of OAT and the adverse outcomes associated with long waiting times, coordinated effort is needed to understand why these differences persist and how they may be addressed through appropriate policy responses.
Identifiants
pubmed: 31830137
doi: 10.1371/journal.pone.0226349
pii: PONE-D-19-13139
pmc: PMC6907755
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0226349Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Drug Alcohol Depend. 2017 Sep 1;178:512-518
pubmed: 28719885
Biol Psychiatry. 2020 Jan 1;87(1):82-88
pubmed: 31420089
Pain. 2017 Jan;158(1):140-148
pubmed: 27984526
Drug Alcohol Depend. 2012 Dec 1;126(3):379-83
pubmed: 22704124
Curr HIV/AIDS Rep. 2018 Apr;15(2):96-112
pubmed: 29460225
Neuropharmacology. 2018 May 15;134(Pt A):121-132
pubmed: 29042317
Health Aff (Millwood). 2015 Jun;34(6):1028-34
pubmed: 26056209
J Subst Abuse Treat. 2015 Jan;48(1):104-11
pubmed: 25218919
J Opioid Manag. 2007 Jul-Aug;3(4):215-23
pubmed: 17957981
PLoS One. 2018 Jun 25;13(6):e0199741
pubmed: 29940033
J Addict Med. 2013 Sep-Oct;7(5):325-34
pubmed: 24091763
Sci Adv. 2019 Oct 02;5(10):eaax9140
pubmed: 31616793
Med Care. 2017 Dec;55(12):985-990
pubmed: 29135769
Annu Rev Public Health. 2015 Mar 18;36:559-74
pubmed: 25581144
Milbank Q. 2015 Sep;93(3):561-83
pubmed: 26350930
Curr HIV/AIDS Rep. 2019 Oct;16(5):381-388
pubmed: 31473903
Psychiatr Serv. 2014 Feb 1;65(2):158-70
pubmed: 24247147
Drug Alcohol Depend. 2014 Dec 1;145:113-20
pubmed: 25456572
Psychiatr Serv. 2014 Feb 1;65(2):146-57
pubmed: 24248468
MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452
pubmed: 28033313
Addict Sci Clin Pract. 2019 Apr 15;14(1):17
pubmed: 30982468
BMC Health Serv Res. 2017 Aug 22;17(1):584
pubmed: 28830504
Am J Public Health. 2015 Aug;105(8):e55-63
pubmed: 26066931
Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S3-11
pubmed: 12738346
Drug Alcohol Depend. 2018 Dec 1;193:142-147
pubmed: 30384321
J Addict Med. 2013 May-Jun;7(3):177-82
pubmed: 23519049
J Subst Abuse Treat. 2011 Dec;41(4):431-9
pubmed: 21821378
Drug Alcohol Depend. 2013 Jul 1;131(1-2):143-8
pubmed: 23306097
J Addict Med. 2015 Sep-Oct;9(5):358-67
pubmed: 26406300
J Subst Abuse Treat. 1999 Jul-Sep;17(1-2):67-77
pubmed: 10435253
Addiction. 2014 Aug;109(8):1320-33
pubmed: 24661272
J Subst Abuse Treat. 2018 Jun;89:67-74
pubmed: 29706175
Health Aff (Millwood). 2017 Dec;36(12):2046-2053
pubmed: 29200340
Subst Abuse Rehabil. 2016 Apr 27;7:27-40
pubmed: 27217808
Cureus. 2018 Dec 14;10(12):e3733
pubmed: 30800543
Am J Public Health. 2014 Aug;104(8):e32-42
pubmed: 24922138
Am J Health Behav. 2006 Sep-Oct;30(5):451-9
pubmed: 16893307